drugset / Trial / NCT06075927
Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety and tolerability of partial HLA-matched VSTs against both CMV and EBV viruses in recipients of allogeneic hematopoietic stem cells with refractory viral infections (CMV and/or EBV). Preliminary evaluation of the efficacy of partial HLA-matched VSTs against both CMV and EBV viruses in recipients of allogeneic hematopoietic stem cells with refractory viral infections (CMV and/or EBV); To monitor the duration and expansion of multi-virus VSTs cells after infusion.
Timeline
- Start
- 2023-11-01
- Primary completion
- 2025-07-30
- Completion
- 2025-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Virus specific T cells | Cell therapy | 1e+07 unknown | Intravenous |
| Subject | Virus specific T cells | Cell therapy | 2e+07 unknown | Intravenous |
| Subject | Virus specific T cells | Cell therapy | 5e+07 unknown | Intravenous |